Antiplatelet therapy with acetylsalicylic acid and the risk of NSAID-associated gastropathy

Abstract

Based on evidence and long-term experience from clinical practice acetylsalicylic acid is considered the most appropriate antiplatelet therapy in patients indicated for secondary prevention of cardiovascular disease who have low risk of gastrointestinal toxicity. In patients possessing high risk additional treatment with proton-pump inhibitors is recommended together with eradication of Helicobacter pylori if present.

Keywords

• acetylsalicylic acid
• pharmacology
• proton pump inhibitor
• peptic ulcer